Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Revenues up 8% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson
 
4Q Revenues: $17.6 billion (+8%)

4Q Earnings: $2.6 billion (earnings were $218 million in 4Q12)

YTD Revenues: $67.2 billion (+3%)

YTD Earnings: $10.5 billion (+9%)

Comments: Pharmaceutical sales were $6.5 billion in the quarter, up 7%, and $25.4 billion for the year, up 4%. Remicade sales were $1.5 billion in the quarter, up 5% and $6.1 billion for the year, up 12%. Simponi sales were up 52% to $181 million in the quarter, and up 48% to $607 million for the year. Stelara sales were $269 million in the quarter, up 30%, and $1.0 billion for the year, up 39%. Risperdal Consta sales were down 7% to $358 million in the quarter, and down 10% for the year to $1.4 billion. Velcade sales were up 43% in the quarter and 18% for the year to $502 million and $1.5 billion, respectively. Consumer sales were flat at $3.7 billion in the quarter, and up 3% for the year, to $14.4 billion. Medical Devices and Diagnostics revenue was $7.4 billion in the quarter, up 14%, and $27.4 billion for the year, up 6%. 2012 results included $4.2 billion charges for product liability expenses, litigation, and costs associated with the DePuy Hip recall.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters